Dano Medical-B (06872.HK) plans to repurchase no more than RMB 50 million of H shares.

Zhitong Finance APP News, TenNor Therapeutics-B (06872.HK) announced that, given that the current market price of the H shares does not fully reflect the company's intrinsic value and business development prospects, the board of directors intends to exercise its powers under the repurchase mandate. As approved by the board of directors, the company will, from time to time and depending on market conditions, repurchase H shares on the open market, with the total repurchase amount not exceeding RMB 50 million. The company will fund the H-share repurchase plan with its own funds.